American Society of Hirudotherapy

The hydrolysis and resynthesis of a single reactive site peptide bond in recombinant antistasin by coagulation factor Xa

Research article published in Archives of biochemistry and biophysics (1992)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Research reportDrug DevelopmentDunwiddie CT et al. · Archives of biochemistry and biophysics, 1992

Abstract

Antistasin (ATS) is a 119-amino acid, leech-derived protein which exhibits selective, tight-binding inhibition of blood coagulation factor Xa. Prolonged incubation of ATS with factor Xa leads to the highly specific hydrolysis of the peptide bond between residues Arg34 and Val35, implicating this peptide bond as the putative reactive site. We report here the preparation of pure, cleaved (modified) recombinant ATS (rATS) and utilize this material to provide additional proof that the cleaved peptide bond is in fact the reactive site. Modified rATS retains strong inhibitory potency against factor Xa as evidenced by a dissociation constant of 166.3 +/- 9.6 pM; four-fold greater than that of native inhibitor, 43.4 +/- 1.4 pM. Incubation of pure, modified rATS with catalytic amounts of factor Xa results in resynthesis of the hydrolyzed peptide bond, achieving an equilibrium near unity between native and modified inhibitors. Specific removal of the newly formed carboxy-terminal Arg residue from modified rATS by carboxypeptidase B treatment obviates its conversion to native inhibitor coincident with the complete loss of inhibitory activity. These results establish that rATS inhibits factor Xa according to a standard mechanism of serine protease inhibitors and support the contention that the Arg34-Val35 peptide bond constitutes the reactive site.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsAmino Acid SequenceAnimalsAnticoagulantsBinding SitesCarboxypeptidase BCarboxypeptidasesChromatography, High Pressure LiquidFactor XaHumansHydrolysisInvertebrate HormonesKineticsLeechesPeptide FragmentsRecombinant ProteinsSubstrate Specificity

Summary

Cleaved recombinant antistasin, a leech-derived factor Xa inhibitor, retained strong inhibitory potency, and factor Xa resynthesized the hydrolyzed Arg34-Val35 bond, confirming this bond as the reactive site of a standard serine-protease-inhibitor mechanism.

Why This Matters for Hirudotherapy

Antistasin is a 119-amino-acid, leech-derived protein that selectively and tightly inhibits blood coagulation factor Xa. This study used purified recombinant antistasin to demonstrate that the Arg34–Val35 peptide bond is the reactive site, showing that modified (cleaved) inhibitor retains potent anti-Xa activity (Kd ~166 pM) and can resynthesize its hydrolyzed bond in the presence of catalytic factor Xa. This work characterizes the mechanism of a specific leech-derived anticoagulant protein. This is a purely biochemical in vitro study using recombinant protein; no live leeches, crude saliva, or clinical or in vivo data are involved.

Citation

Reference (Vancouver style)

Dunwiddie CT, Vlasuk GP, Nutt EM. The hydrolysis and resynthesis of a single reactive site peptide bond in recombinant antistasin by coagulation factor Xa. Arch Biochem Biophys. 1992;294(2):647-653. doi:10.1016/0003-9861(92)90737-h. PMID: 1567219

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 27, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.